Barbara MacGregor‐Cortelli

1.4k citations

12 papers · 1.1k indexed · h-index 10

Impact in

Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Genetics 6
- Chronic Lymphocytic Leukemia Research 6
Pathology and Forensic Medicine 9
- Lymphoma Diagnosis and Treatment 9

Co-authors: Owen A. O’Connor Andrew D. Zelenetz Craig H. Moskowitz Carol S. Portlock Paul A. Hamlin James R. Wright David P. Schenkein David J. Straus
Journals: Journal of Clinical Oncology (4 papers)Blood (3 papers)British Journal of Haematology (2 papers)Clinical Oncology (1 paper)European Journal of Cancer Supplements (1 paper)
Partner nations: United States

In The Last Decade

Barbara MacGregor‐Cortelli

12 papers receiving 1.1k citations

Peers

Countries citing papers authored by Barbara MacGregor‐Cortelli

Since Specialization

Citations

This map shows the geographic impact of Barbara MacGregor‐Cortelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara MacGregor‐Cortelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara MacGregor‐Cortelli more than expected).

Fields of papers citing papers by Barbara MacGregor‐Cortelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara MacGregor‐Cortelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara MacGregor‐Cortelli. The network helps show where Barbara MacGregor‐Cortelli may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Barbara MacGregor‐Cortelli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Barbara MacGregor‐Cortelli Line = papers co-authored together Barbara MacGregor‐Cortelli links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work
1	Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies Journal of Clinical Oncology ·Owen A. O’Connor, Steven M. Horwitz, Paul A. Hamlin, Carol S. Portlock, Craig H. Moskowitz, Debra Sarasohn, Ellen Neylon, Liu JianRong, Marc A. McWilliams, Barbara MacGregor‐Cortelli, Molly Bruce Patterson, Venkatraman Seshan, L. M. HARROD, Martin Fleisher, Diane R. Mould, M.I. Saunders, Andrew D. Zelenetz	2009	131
2	Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions Blood ·Alexander G. Marneros, Marc E. Grossman, David N. Silvers, Sameera Husain, Gerard J. Nuovo, Barbara MacGregor‐Cortelli, Ellen Neylon, Molly Bruce Patterson, Owen A. O’Connor, Jasmine Zain	2009	18
3	Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma British Journal of Haematology ·Owen A. O’Connor, Paul A. Hamlin, Carol S. Portlock, Craig H. Moskowitz, Ariela Noy, David J. Straus, Barbara MacGregor‐Cortelli, Ellen Neylon, Debra Sarasohn, Francisco Quijano, Diane R. Mould, Martin Fleischer, Andrew D. Zelenetz, L. M. HARROD, Steven M. Horwitz	2007	68
4	Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL) Journal of Clinical Oncology ·Yang, Paul A. Hamlin, Craig H. Moskowitz, David Straus, Ariela Noy, James R. Wright, Ellen Neylon, Barbara MacGregor‐Cortelli, C. Portlock, Andrew D. Zelenetz	2007	9
5	An Electrodiagnostic Evaluation of the Effect of Pre-existing Peripheral Nervous System Disorders in Patients Treated with the Novel Proteasome Inhibitor Bortezomib Clinical Oncology ·Michael D. Stubblefield, Susan F. Slovin, Barbara MacGregor‐Cortelli, Stephanie Masotti, Howard I. Scher, James R. Wright, Dixie Esseltine, David P. Schenkein, Owen A. O’Connor	2006	17
6	Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? British Journal of Haematology ·John F. Gerecitano, André Goy, James R. Wright, Barbara MacGregor‐Cortelli, Ellen Neylon, Mithat Gönen, Dixie Esseltine, Anthony Boral, David P. Schenkein, Klaus J. Busam, Julie Teruya‐Feldstein, Dana L. Sachs, Owen A. O’Connor	2006	36
7	Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies Journal of Clinical Oncology ·Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz, Chun-hui LIU, Miriam Rademacher, Barbara MacGregor‐Cortelli, S. R. Lee, Craig H. Moskowitz, Carol S. Portlock, Steven M. Horwitz, Andrew D. Zelenetz, Stanley Frankel, Victoria M. Richon, Paul A. Marks, William Kevin Kelly	2005	345
8	Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response. Blood ·John F. Gerecitano, André Goy, Barbara MacGregor‐Cortelli, Ellen Neylon, James R. Wright, Dixie Esseltine, David P. Schenkein, Mithat Gönen, Owen A. O’Connor	2005	3
9	A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition. Blood ·Owen A. O’Connor, James R. Wright, Craig H. Moskowitz, Barbara MacGregor‐Cortelli, David J. Straus, Andrew Evans, Jane N. Winter, Omer N. Koç, N. Horvath, Susan Blumel, Julie M. Vose, David P. Schenkein, Andrew D. Zelenetz	2004	16
10	Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Journal of Clinical Oncology ·Owen A. O’Connor, James R. Wright, Craig H. Moskowitz, Stephanie Masotti, Barbara MacGregor‐Cortelli, Michael D. Stubblefield, David J. Straus, Carol S. Portlock, Paul A. Hamlin, Elizabeth Choi, Francisco Quijano, Dixie Esseltine, Elizabeth Trehu, Julian Adams, David P. Schenkein, Andrew D. Zelenetz	2004	461
11	Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. PubMed ·Owen A. O’Connor, James R. Wright, Craig H. Moskowitz, Stephanie Masotti, Barbara MacGregor‐Cortelli, Paul A. Hamlin, David J. Straus, Elizabeth Trehu, David P. Schenkein, Andrew D. Zelenetz	2004	5
12	1009 Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas European Journal of Cancer Supplements ·Angela Gerolamo, James R. Wright, Craig H. Moskowitz, David J. Straus, Barbara MacGregor‐Cortelli, Stephanie Masotti, Pamela M. Choi, David P. Schenkein, Andrew D. Zelenetz	2003	10

About Barbara MacGregor‐Cortelli

Barbara MacGregor‐Cortelli is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Dermatology and Oncology, having authored 12 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (6 papers), T-cell and Retrovirus Studies (3 papers), Ubiquitin and proteasome pathways (3 papers), Viral-associated cancers and disorders (2 papers), Multiple Myeloma Research and Treatments (2 papers), Cutaneous lymphoproliferative disorders research (2 papers) and Acute Myeloid Leukemia Research (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (500 citations), Genetics (248 citations), Hematology (234 citations), Dermatology (149 citations) and Oncology (424 citations). Barbara MacGregor‐Cortelli has collaborated with scholars based in United States. Frequent co-authors include Owen A. O’Connor, Andrew D. Zelenetz, Craig H. Moskowitz, Carol S. Portlock, Paul A. Hamlin, James R. Wright, David P. Schenkein, David J. Straus, Steven M. Horwitz and Dixie Esseltine. Their work appears in journals such as Journal of Clinical Oncology, Blood, British Journal of Haematology, Clinical Oncology and European Journal of Cancer Supplements.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact